Company intelligence / Profile preview

Drive Therapeutics

Durham, North Carolina, United Statesdrivetherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Drive Therapeutics develops aptamer-based therapeutics for retinal diseases such as wAMD and DR/DME. Their candidates are designed to inhibit novel pathological targets beyond VEGF, aiming to improve efficacy and reduce dosing frequency. No clinical results have been published yet.

Therapeutic areas: Ophthalmology
Modalities: Aptamers (nucleic acid-based therapeutics)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships disclosed

Beyond the preview

Go deeper on Drive Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Drive Therapeutics.

Explore the full profile